[High-dose progestational contraception: side effects].
Progestational contraception (CMP) is rarely used. In France, its indications are not clearly defined. The prescription is justified when there is a contra-indication to estrogen use (uterus fibroids, endometrial hyperplasia, endometriosis, fibro-cystic disease of the breast). The side effects are menstruation disorders (metrorrhagias, amenorrhea), weight gain, atherogenic metabolic changes. Actually, nor-pregnane derivatives, which correctly block ovulation, do not seem to have a deleterious effect on glucide and lipid parameters. At last, it is not sure that CMP may be prescribed to a patient previously treated for a breast cancer.
A
A
Gorins
D001161:Arteriosclerosis / Q000139:chemically induced; D001943:Breast Neoplasms / Q000188:drug therapy; D003278:Contraceptives, Oral, Hormonal / Q000009:adverse effects*; D000075202:Contraindications; D004714:Endometrial Hyperplasia / Q000188:drug therapy; D004715:Endometriosis / Q000188:drug therapy; D004967:Estrogens; D005260:Female; D005348:Fibrocystic Breast Disease / Q000188:drug therapy; D006801:Humans; D007889:Leiomyoma / Q000188:drug therapy; D008599:Menstruation Disturbances / Q000139:chemically induced; D045167:Progesterone Congeners / Q000009:adverse effects*; D014594:Uterine Neoplasms / Q000188:drug therapy; D015430:Weight Gain / Q000187:drug effects
D003278:Contraceptives, Oral, Hormonal; D004967:Estrogens; D045167:Progesterone Congeners
La contraception macroprogestative: inconvénients.